🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for Undifferentiated Carcinoma

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib A Real World Study of Ensartinib in Advanced ALK-positive NSCLC NCT05498064n/a1 site📍 Beijing Peking Union Medical College Hospital · Tests: Ensartinib Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix NCT04723095n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: Follow-Up, Medical Chart Review DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542NA1 site📍 Hangzhou Zhejiang Provincial People's Hospital · Tests: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264) DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. NCT07440290Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Dabrafenib, Trametinib Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions NCT06612827n/a1 site📍 Caen Centre Francois Baclesse · Tests: organoid etablishment Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601Phase 2138 sites📍 Birmingham📍 Athens📍 Augusta National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388Phase 13 sites📍 Birmingham📍 St Louis📍 Houston M.D. Anderson Cancer Center · Tests: G207 Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels NCT05525338Phase 48 sites📍 Villejuif📍 Nijmegen📍 Maastricht University Medical Center Groningen · Tests: Alectinib XL092 and Cemiplimab in BRAF WT Thyroid Cancer NCT06902376Phase 12 sites📍 Boston📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Cemiplimab, XL092 NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) NCT06079333Phase 21 site📍 Leiden Leiden University Medical Center · Tests: dabrafenib/trametinib Toripalimab With Chemotherapy for Sinus Cancer NCT06940180Phase 22 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Toripalimab, Carboplatin, Docetaxel, Radiation Therapy, Cisplatin Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189Phase 145 sites📍 Lexington📍 Louisville📍 Baltimore BioNTech SE · Tests: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC NCT06765109Phase 3159 sites📍 Glendale📍 Newport Beach📍 Orange Nuvalent Inc. · Tests: Neladalkib (NVL-655), Alectinib [177Lu]Lu-AKIR001 First-in-human Study NCT06639191EARLY Phase 11 site📍 Stockholm Karolinska University Hospital · Tests: [177Lu]Lu-AKIR001 Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer NCT07777536Phase 21 site📍 Shanghai Fudan University · Tests: Selective coverage radiotherapy, comprehensive coverage radiotherapy A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172Phase 110 sites📍 Beverly Hills📍 Santa Monica📍 Houston Epkin · Tests: OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial NCT07485569Phase 11 site📍 Nijmegen Radboud University Medical Center · Tests: Personalised treatment Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496Phase 1, Phase 23 sites📍 Gilbert📍 Tucson📍 Seattle University of Arizona · Tests: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors NCT06176989Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Enasidenib NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) NCT06239272Phase 1, Phase 27 sites📍 Atlanta📍 Chicago📍 Baton Rouge St. Jude Children's Research Hospital · Tests: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016Phase 117 sites📍 Fullerton📍 Orange📍 Edwards Astellas Pharma Global Development, Inc. · Tests: gilteritinib DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. NCT05768178Phase 2, Phase 316 sites📍 Belfast📍 Birmingham📍 Bristol Cancer Research UK · Tests: Vemurafenib, Cobimetinib Sacituzumab govitEcan in THYroid Cancers NCT06235216Phase 211 sites📍 Barcelona📍 Ferrol📍 Hospitalet de Llobregat (Barcelona) Grupo Espanol de Tumores Neuroendocrinos · Tests: Sacituzumab govitecan Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer NCT06374602Phase 21 site📍 Saint Petersburg Saint Petersburg State University, Russia · Tests: Pembrolizumab + Lenvatinib Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study NCT05946577n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris Pembrolizumab in Locally Advanced Sinonasal Carcinoma NCT05925491Phase 21 site📍 Pavia Istituti Clinici Scientifici Maugeri SpA · Tests: Pembrolizumab, Cisplatin, Docetaxel, Carboplatin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy